ClinicalTrials.gg
CompletedNCT05260021SURPASS-PEDSUpdated Sep 26, 2025Results posted

A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

A Phase 3 interventional study of Tirzepatide Dose 1 and Tirzepatide Dose 2 in Type2 Diabetes, Diabetes Mellitus and Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 51 sites in 9 countries. Open to participants aged 10 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-09-26.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
10 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company — 10 open to participants now, 21 under way, 11 of them phase 3. Diabetes Mellitus, Type 2 · Eli Lilly and Company.

Enrollment
144th of 232
99 · median 181
Started
2022
with 10 others
Phase 3
85 of 238
6 open now
Registered
179th of 238
by date

Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 144th largest by enrollment of the 232 interventional ones that give a count, is one of 11 that started in 2022, is one of 85 in phase 3, and was the 179th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

10 of the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 10 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both.

The overall study will last about 60 weeks with up to 14 clinic visits and 6 phone visits. Clinic visits will include blood sample collection, physical exam and questionnaire.

03

Conditions studied

  • Type2 Diabetes
  • Diabetes Mellitus
  • Diabetes Mellitus, Type 2
  • T2D
  • T2DM (Type 2 Diabetes Mellitus)
  • Glucose Metabolism Disorders
  • Endocrine System Diseases
  • Metabolic Disease

Keywords

  • GLP-1 RA
  • Glucose-dependent insulinotropic polypeptide (GIP)
  • glucagon-like peptide-1 (GLP-1)
  • GIP/GLP-1 dual receptor agonist
  • Incretins
04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 99 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
10 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 10 to below 18 years at screening visit
  • Have type 2 diabetes, treated with diet and exercise and metformin and/or basal insulin. Metformin and/or basal insulin dose must be stable for at least 90 days prior to study screening.
  • Have >6.5% to ≤11% at screening
  • Have body weight ≥50 kilogram (kg) 110 pounds and of >85th percentile of the general age and gender-matched population for that country or region.

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 diabetes mellitus (T1DM), or positive GAD65 or IA2 antibodies
  • After the T2DM diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome
  • Have had ≥1 episode of severe hypoglycemia and/or ≥1 episode of hypoglycemic unawareness within the last 6 months.
  • Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).
  • Had chronic or acute pancreatitis any time prior to study entry
  • Female participants who are pregnant or breast feeding or intending to become pregnant.
  • Using prescription or over the counter medications for weight loss within 90 days of the screening visit.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    Tirzepatide Dose 1

    Double-Blind: Participants receive Tirzepatide by weekly subcutaneous (SC) injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 1 is reached. Open-Label: Participants will continue to receive Tirzepatide at the last dose level

    Drug: Tirzepatide Dose 1

  • Experimental
    Tirzepatide Dose 2

    Double-Blind: Participants receive Tirzepatide by weekly SC injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 2 is reached. Open-Label: Participants will continue to receive Tirzepatide at the last dose level

    Drug: Tirzepatide Dose 2

  • Placebo comparator
    Placebo

    Double-Blind: Participants receive placebo during the 30-week double-blind period. Open-Label: Participants will switch to Tirzepatide by weekly SC injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 1 is reached.

    Drug: Tirzepatide Dose 1 · Drug: Placebo

Interventions

  • DrugTirzepatide Dose 1

    Administered SC

  • DrugTirzepatide Dose 2

    Administered SC

  • DrugPlacebo

    Administered SC

This study also gives Tirzepatide. No intervention listed here names it: that was found by reading the record.

07

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares)

    Time frame: Baseline, Week 30

Secondary outcomes

  1. Change From Baseline in HbA1c (Individual Doses)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares).

    Time frame: Baseline, Week 30

  2. Percentage of Participants Who Achieve ≤6.5% of HbA1c

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing.

    Time frame: Week 30

  3. Change From Baseline in Body Mass Index (BMI) Standard Deviation Score (Age and Sex-matched)

    BMI SDS (age and sex matched), calculated using the World Health Organization (WHO) growth reference standards. BMI is calculated as weight in kilograms divided by height in meters squared (kg/m²) and converted to a Z-score (SDS) based on WHO reference data. A Z-score of 0 represents the population mean for a given age and sex. A BMI SDS between -1 and +1 is considered normal. Obesity is defined as BMI SDS \> +2. Reductions in BMI SDS indicate improvement in weight status for individuals with obesity. LS mean was determined by the ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares)

    Time frame: Baseline, Week 30

  4. Change From Baseline in Fasting Serum Glucose (FSG)

    LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares).

    Time frame: Baseline, Week 30

  5. Percent Change From Baseline in BMI

    LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares).

    Time frame: Baseline, Week 30

  6. Percentage of Participants Who Achieve <5.7% of HbA1c

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing.

    Time frame: Week 30

  7. Percentage of Participants Who Achieve <7.0% of HbA1c

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing.

    Time frame: Week 30

  8. Percent Change From Baseline for Serum Lipid Levels

    Geometric LS mean was determined by the MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Baseline Antihyperglycemic medication + Baseline Age group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 30

  9. Change From Baseline in Height Standard Deviation Score (SDS)

    Height SDS (age and sex-matched), calculated using the World Health Organization (WHO) growth reference standards. Height SDS is derived by comparing a child's height to the median height for their age and sex in the WHO reference population, then expressing the difference in standard deviation units (Z-scores). A Z-score of 0 represents the population mean. A Height SDS below -2 indicates short stature. Positive changes in Height SDS from baseline reflect improvement in growth velocity or catch-up growth. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Baseline Age group + Baseline Antihyperglycemic medication + Treatment + Time + Treatment\*Time(Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured

    Time frame: Baseline, Week 30

  10. Change From Baseline in Weight SDS

    Weight SDS, calculated using Centers for Disease Control and Prevention (CDC) growth reference standards. Weight SDS is derived by comparing a child's weight to median weight for their age and sex in the CDC reference population, then expressing the difference in standard deviation units (Z-scores). A Z-score of 0 represents the population mean for a given age and sex. A Weight SDS below -2 may indicate underweight status, while a Weight SDS above +2 may indicate overweight or obesity. Change from baseline Weight SDS reflects shifts in growth trajectory, with positive changes indicating weight gain and negative changes indicating weight reduction. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Baseline Age group + Baseline Antihyperglycemic medication + Treatment + Time + Treatment\*Time(Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured

    Time frame: Baseline, Week 30

  11. Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale

    The PedsQL Measurement Model measures health-related quality of life (HRQOL) in children (ages 8 to 12) and teenagers (ages 13 to 18). The 23-item PedsQL Generic Core Scale includes physical, emotional, social, and school functioning dimensions. The PedsQL Generic Core yields two summary scores: Physical Summary and Psychosocial Summary. Scores are transformed on a 0-100 scale, with higher scores indicating better functioning. Each item is scored from 0 (never) to 4 (almost always). Items are reverse scored and linearly transformed to a 0-100 scale so that higher scores indicate better HRQOL; the total score therefore ranges from 0 (worst) to 100 (best). Higher scores indicate better health-related quality of life. LS mean was determined by the MMRM model for post-baseline measures: Variable = Baseline + Baseline Antihyperglycemic Medication + Baseline Age Group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured.

    Time frame: Baseline, Week 52

  12. Change From Baseline PedsQL (3.2) Diabetic Module

    The PedsQL 3.2 Diabetes Module has 33 items for ages 13 years and older, and 32 items (1 less item for the Worry Scale) for ages 2 to 12 years. The 5 dimensions consist of diabetes symptoms (15 items), treatment barriers (5 items), treatment adherence (6 items), worry \[2 items (3 for teens and adults)\] and communication (4 items). Item scaling is a 5-point scale from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores reflect fewer problems and better functioning. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment + Time + Treatment\*Time(Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance- Covariance structure (Change from Baseline) = Unstructured.

    Time frame: Baseline, Week 52

  13. Population Pharmacokinetics (PopPK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide

    The steady-state AUCs were estimated from Tirzepatide concentrations at Weeks 0, 7, 16, and 29 using the population PK model by treatment group.

    Time frame: Week 0: after the first dose anytime on the same day. Weeks 7, 16, and 29: 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours post-dose, as assigned by IWRS.

08

Results

Posted Sep 26, 2025

Participant flow

Double-blind Period (30 Weeks)
Participant flow — Double-blind Period (30 Weeks)
Milestone5 Milligram (mg) Tirzepatide/5 mg Tirzepatide10 mg Tirzepatide/10 mg TirzepatidePlacebo/5 mg Tirzepatide
Started323334
Received atleast one dose of study drug323334
Safety analysis set 1323334
Completed292932
Not completed342
Withdrew: Adverse event200
Withdrew: Withdrawal by subject121
Withdrew: Lost to follow-up001
Withdrew: Withdrawal due to caregiver circumstances010
Withdrew: Incorrectly enrolled010
Open-label Period (22 Weeks)
Participant flow — Open-label Period (22 Weeks)
Milestone5 Milligram (mg) Tirzepatide/5 mg Tirzepatide10 mg Tirzepatide/10 mg TirzepatidePlacebo/5 mg Tirzepatide
Started292932
Safety analysis set 2323332
Completed292932
Not completed000
Safety Follow-up Period (4 Weeks)
Participant flow — Safety Follow-up Period (4 Weeks)
Milestone5 Milligram (mg) Tirzepatide/5 mg Tirzepatide10 mg Tirzepatide/10 mg TirzepatidePlacebo/5 mg Tirzepatide
Started292932
Completed292932
Not completed000

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares)

Time frame:
Baseline, Week 30
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg)
percentage of HbA1cPooled Doses of Tirzepatide (5 mg, 10 mg)Placebo
Change From Baseline in Hemoglobin A1c (HbA1c) (Pooled Doses of Tirzepatide 5 mg and 10 mg)-2.03 ± 0.165-0.23 ± 0.229
Statistical analysis
  • Pooled Doses of Tirzepatide (5 mg, 10 mg) vs Placebo · ANCOVA · p = <0.001 · Ls mean difference (final values): -1.80 · 95% CI -2.35 to -1.25
SecondaryChange From Baseline in HbA1c (Individual Doses)

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares).

Time frame:
Baseline, Week 30
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline in HbA1c (Individual Doses)
percentage of HbA1c5 mg Tirzepatide10 mg TirzepatidePlacebo
Change From Baseline in HbA1c (Individual Doses)-1.90 ± 0.236-2.16 ± 0.232-0.23 ± 0.229
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference (final values): -1.67 · 95% CI -2.31 to -1.02
  • 10 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference (final values): -1.93 · 95% CI -2.57 to -1.29
SecondaryPercentage of Participants Who Achieve ≤6.5% of HbA1c

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing.

Time frame:
Week 30
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve ≤6.5% of HbA1c
percentage of participants5 mg Tirzepatide10 mg TirzepatidePooled Doses of Tirzepatide (5mg,10mg)Placebo
Percentage of Participants Who Achieve ≤6.5% of HbA1c66.480.673.628.2
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Risk difference (rd): 40.1 · 95% CI 18.6 to 61.7
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Risk difference (rd): 51.6 · 95% CI 31.1 to 72.2
  • Pooled Doses of Tirzepatide (5mg,10mg) vs Placebo · Regression, Logistic · p = <0.001 · Risk difference (rd): 45.8 · 95% CI 27.5 to 64.1
SecondaryChange From Baseline in Body Mass Index (BMI) Standard Deviation Score (Age and Sex-matched)

BMI SDS (age and sex matched), calculated using the World Health Organization (WHO) growth reference standards. BMI is calculated as weight in kilograms divided by height in meters squared (kg/m²) and converted to a Z-score (SDS) based on WHO reference data. A Z-score of 0 represents the population mean for a given age and sex. A BMI SDS between -1 and +1 is considered normal. Obesity is defined as BMI SDS \> +2. Reductions in BMI SDS indicate improvement in weight status for individuals with obesity. LS mean was determined by the ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares)

Time frame:
Baseline, Week 30
Reported as:
Least squares mean · Z-score
Change From Baseline in Body Mass Index (BMI) Standard Deviation Score (Age and Sex-matched)
Z-score5 mg Tirzepatide10 mg TirzepatidePooled Doses of Tirzepatide (5mg,10mg)Placebo
Change From Baseline in Body Mass Index (BMI) Standard Deviation Score (Age and Sex-matched)-0.45 ± 0.072-0.76 ± 0.072-0.60 ± 0.050-0.09 ± 0.069
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · ANCOVA · p = < 0.001 · Ls mean difference (final values): -0.36 · 95% CI -0.55 to -0.16
  • 10 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference (final values): -0.66 · 95% CI -0.86 to -0.47
  • Pooled Doses of Tirzepatide (5mg,10mg) vs Placebo · ANCOVA · p = < 0.001 · Ls mean difference (final values): -0.51 · 95% CI -0.68 to -0.34
SecondaryChange From Baseline in Fasting Serum Glucose (FSG)

LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares).

Time frame:
Baseline, Week 30
Reported as:
Least squares mean · milligram per deciliter (mg/dL)
Change From Baseline in Fasting Serum Glucose (FSG)
milligram per deciliter (mg/dL)5 mg Tirzepatide10 mg TirzepatidePooled Doses of Tirzepatide (5mg,10mg)Placebo
Change From Baseline in Fasting Serum Glucose (FSG)-35.5 ± 7.76-50.6 ± 7.40-43.0 ± 5.42-6.6 ± 7.36
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · ANCOVA · p = 0.007 · Ls mean difference (final values): -28.9 · 95% CI -49.7 to -8.0
  • 10 mg Tirzepatide vs Placebo · ANCOVA · p = < 0.001 · Ls mean difference (final values): -44.0 · 95% CI -64.3 to -23.6
  • Pooled Doses of Tirzepatide (5mg,10mg) vs Placebo · ANCOVA · p = < 0.001 · Ls mean difference (final values): -36.4 · 95% CI -54.2 to -18.6
SecondaryPercent Change From Baseline in BMI

LS mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares).

Time frame:
Baseline, Week 30
Reported as:
Least squares mean · Percent Change of BMI
Percent Change From Baseline in BMI
Percent Change of BMI5 mg Tirzepatide10 mg TirzepatidePooled Doses of Tirzepatide (5mg,10mg)Placebo
Percent Change From Baseline in BMI-6.73 ± 1.155-11.07 ± 1.154-8.90 ± 0.808-0.55 ± 1.107
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · ANCOVA · p = < 0.001 · Ls mean difference (final values): -6.18 · 95% CI -9.31 to -3.05
  • 10 mg Tirzepatide vs Placebo · ANCOVA · p = < 0.001 · Ls mean difference (final values): -10.52 · 95% CI -13.67 to -7.38
  • Pooled Doses of Tirzepatide (5mg,10mg) vs Placebo · ANCOVA · p = < 0.001 · Ls mean difference (final values): -8.35 · 95% CI -11.05 to -5.66
SecondaryPercentage of Participants Who Achieve <5.7% of HbA1c

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing.

Time frame:
Week 30
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve <5.7% of HbA1c
percentage of participants5 mg Tirzepatide10 mg TirzepatidePooled Doses of Tirzepatide (5mg,10mg)Placebo
Percentage of Participants Who Achieve <5.7% of HbA1c44.156.250.215.9
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Regression, Logistic · p = 0.006 · Risk difference (rd): 29.5 · 95% CI 8.6 to 50.3
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = < 0.001 · Risk difference (rd): 39.5 · 95% CI 18.8 to 60.2
  • Pooled Doses of Tirzepatide (5mg,10mg) vs Placebo · Regression, Logistic · p = < 0.001 · Risk difference (rd): 34.6 · 95% CI 17 to 52.1
SecondaryPercentage of Participants Who Achieve <7.0% of HbA1c

HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Imputed data includes observed value and imputed value if endpoint measure is missing.

Time frame:
Week 30
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieve <7.0% of HbA1c
percentage of participants5 mg Tirzepatide10 mg TirzepatidePooled Doses of Tirzepatide (5mg,10mg)Placebo
Percentage of Participants Who Achieve <7.0% of HbA1c79.684.582.137.4
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Regression, Logistic · p = < 0.001 · Risk difference (rd): 43.4 · 95% CI 22.3 to 64.4
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = < 0.001 · Risk difference (rd): 47.1 · 95% CI 26.4 to 67.7
  • Pooled Doses of Tirzepatide (5mg,10mg) vs Placebo · Regression, Logistic · p = < 0.001 · Risk difference (rd): 45.2 · 95% CI 26.3 to 64.1
SecondaryPercent Change From Baseline for Serum Lipid Levels

Geometric LS mean was determined by the MMRM model for post-baseline measures: log(Actual Measurement/Baseline) = log(Baseline) + Baseline Antihyperglycemic medication + Baseline Age group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 30
Reported as:
Geometric least squares mean · Percent change of Serum Lipid Levels
Percent Change From Baseline for Serum Lipid Levels
Percent change of Serum Lipid Levels5 mg Tirzepatide10 mg TirzepatidePooled Doses of Tirzepatide (5mg,10mg)Placebo
Serum Cholesterol-8.07 ± 2.319-13.82 ± 2.115-10.99 ± 1.5645.07 ± 2.456
Serum High-density lipoprotein (HDL) Cholesterol 3RD generation, enzymatic5.56 ± 3.2691.72 ± 3.0873.62 ± 2.2470.92 ± 2.887
Serum Triglycerides-27.6 ± 4.816-35.8 ± 4.165-31.8 ± 3.165-1.74 ± 6.022
Serum low-density lipoprotein (LDL) Cholesterol Combined-6.08 ± 3.870-11.97 ± 3.540-9.07 ± 2.6189.84 ± 4.185
Serum very low-density lipoprotein (VLDL) Cholesterol Combined-25.9 ± 5.005-34.8 ± 4.293-30.5 ± 3.276-0.26 ± 6.211
SecondaryChange From Baseline in Height Standard Deviation Score (SDS)

Height SDS (age and sex-matched), calculated using the World Health Organization (WHO) growth reference standards. Height SDS is derived by comparing a child's height to the median height for their age and sex in the WHO reference population, then expressing the difference in standard deviation units (Z-scores). A Z-score of 0 represents the population mean. A Height SDS below -2 indicates short stature. Positive changes in Height SDS from baseline reflect improvement in growth velocity or catch-up growth. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Baseline Age group + Baseline Antihyperglycemic medication + Treatment + Time + Treatment\*Time(Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured

Time frame:
Baseline, Week 30
Reported as:
Least squares mean · Z-score
Change From Baseline in Height Standard Deviation Score (SDS)
Z-score5 mg Tirzepatide10 mg TirzepatidePooled Doses of Tirzepatide (5mg,10mg)Placebo
Change From Baseline in Height Standard Deviation Score (SDS)-0.092 ± 0.0275-0.11 ± 0.0274-0.100 ± 0.0194-0.11 ± 0.0259
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = 0.708 · Ls mean difference (final values): 0.014 · 95% CI -0.061 to 0.089
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = 0.976 · Ls mean difference (final values): -0.001 · 95% CI -0.076 to 0.074
  • Pooled Doses of Tirzepatide (5mg,10mg) vs Placebo · Mixed Models Analysis · p = 0.841 · Ls mean difference (final values): 0.007 · 95% CI -0.058 to 0.071
SecondaryChange From Baseline in Weight SDS

Weight SDS, calculated using Centers for Disease Control and Prevention (CDC) growth reference standards. Weight SDS is derived by comparing a child's weight to median weight for their age and sex in the CDC reference population, then expressing the difference in standard deviation units (Z-scores). A Z-score of 0 represents the population mean for a given age and sex. A Weight SDS below -2 may indicate underweight status, while a Weight SDS above +2 may indicate overweight or obesity. Change from baseline Weight SDS reflects shifts in growth trajectory, with positive changes indicating weight gain and negative changes indicating weight reduction. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Baseline Age group + Baseline Antihyperglycemic medication + Treatment + Time + Treatment\*Time(Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured

Time frame:
Baseline, Week 30
Reported as:
Least squares mean · Z-score
Change From Baseline in Weight SDS
Z-score5 mg Tirzepatide10 mg TirzepatidePooled Doses of Tirzepatide (5mg,10mg)Placebo
Change From Baseline in Weight SDS-0.38 ± 0.0600-0.50 ± 0.0594-0.44 ± 0.0422-0.099 ± 0.0570
Statistical analysis
  • 5 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = < 0.001 · Ls mean difference (final values): -0.29 · 95% CI -0.45 to -0.12
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = < 0.001 · Ls mean difference (final values): -0.4 · 95% CI -0.57 to -0.24
  • Pooled Doses of Tirzepatide (5mg,10mg) vs Placebo · Mixed Models Analysis · p = < 0.001 · Ls mean difference (final values): -0.34 · 95% CI -0.49 to -0.2
SecondaryChange From Baseline in Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale

The PedsQL Measurement Model measures health-related quality of life (HRQOL) in children (ages 8 to 12) and teenagers (ages 13 to 18). The 23-item PedsQL Generic Core Scale includes physical, emotional, social, and school functioning dimensions. The PedsQL Generic Core yields two summary scores: Physical Summary and Psychosocial Summary. Scores are transformed on a 0-100 scale, with higher scores indicating better functioning. Each item is scored from 0 (never) to 4 (almost always). Items are reverse scored and linearly transformed to a 0-100 scale so that higher scores indicate better HRQOL; the total score therefore ranges from 0 (worst) to 100 (best). Higher scores indicate better health-related quality of life. LS mean was determined by the MMRM model for post-baseline measures: Variable = Baseline + Baseline Antihyperglycemic Medication + Baseline Age Group + Treatment + Time + Treatment\*Time (Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale
score on a scale5 mg Tirzepatide10 mg TirzepatidePlacebo/5 mg TirzepatidePooled Doses of Tirzepatide (5mg,10mg)
Physical Functioning Score4.26 ± 2.0343.06 ± 2.0925.03 ± 2.1423.66 ± 1.456
Emotional Functioning Score4.35 ± 3.5064.11 ± 3.6016.78 ± 3.7054.23 ± 2.514
Social Functioning Score4.16 ± 2.6283.00 ± 2.6964.54 ± 2.7643.58 ± 1.878
School Functioning Score13.30 ± 3.0950.18 ± 3.15212.03 ± 3.2396.74 ± 2.197
Psychosocial Health Summary Score7.82 ± 2.4822.20 ± 2.5337.47 ± 2.6055.01 ± 1.767
Physical Health Summary Score4.26 ± 2.0343.06 ± 2.0925.03 ± 2.1423.66 ± 1.456
Total Score6.65 ± 2.1142.45 ± 2.1636.61 ± 2.2204.55 ± 1.507
SecondaryChange From Baseline PedsQL (3.2) Diabetic Module

The PedsQL 3.2 Diabetes Module has 33 items for ages 13 years and older, and 32 items (1 less item for the Worry Scale) for ages 2 to 12 years. The 5 dimensions consist of diabetes symptoms (15 items), treatment barriers (5 items), treatment adherence (6 items), worry \[2 items (3 for teens and adults)\] and communication (4 items). Item scaling is a 5-point scale from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores reflect fewer problems and better functioning. LS mean was determined by MMRM model for post-baseline measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment + Time + Treatment\*Time(Type III sum of squares). Variance-Covariance structure (Actual Value) = Unstructured. Variance- Covariance structure (Change from Baseline) = Unstructured.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline PedsQL (3.2) Diabetic Module
score on a scale5 mg Tirzepatide10 mg TirzepatidePlacebo/5 mg TirzepatidePooled Doses of Tirzepatide (5mg,10mg)
Diabetes Management Summary Score7.21 ± 2.6698.60 ± 2.7335.25 ± 2.8727.90 ± 1.907
Total Score8.79 ± 2.3108.74 ± 2.3746.03 ± 2.4898.76 ± 1.657
SecondaryPopulation Pharmacokinetics (PopPK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide

The steady-state AUCs were estimated from Tirzepatide concentrations at Weeks 0, 7, 16, and 29 using the population PK model by treatment group.

Time frame:
Week 0: after the first dose anytime on the same day. Weeks 7, 16, and 29: 1 to 24 hours, 24 to 96 hours, or 120 to 168 hours post-dose, as assigned by IWRS.
Reported as:
Mean · nanogram*hour per milliliter (ng*hr/mL)
Population Pharmacokinetics (PopPK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide
nanogram*hour per milliliter (ng*hr/mL)5 mg Tirzepatide10 mg Tirzepatide
Population Pharmacokinetics (PopPK): Steady State Area Under the Concentration Curve (AUC) of Tirzepatide92100 (85700 to 98600)184000 (171000 to 197000)

Adverse events

Collected over Baseline Up to Week 56. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
5 mg Tirzepatide / Double-Blind Period0/32 (0%)1/32 (3.1%)17/32 (53.1%)
TZP 10mg / Double-Blind Period0/33 (0%)1/33 (3%)19/33 (57.6%)
Placebo / Double-Blind Period0/34 (0%)1/34 (2.9%)11/34 (32.4%)
TZP 5mg / 5mg Open-Label and Safety Follow-Up Period0/32 (0%)1/32 (3.1%)10/32 (31.3%)
TZP 10mg / 10mg Open-Label and Safety Follow-Up Period0/33 (0%)1/33 (3%)7/33 (21.2%)
Placebo/TZP 5mg Open-Label and Safety Follow-Up Period0/32 (0%)0/32 (0%)8/32 (25%)
Most frequent serious events
Most frequent serious events
Event5 mg Tirzepatide / Double-Blind PeriodTZP 10mg / Double-Blind PeriodPlacebo / Double-Blind PeriodTZP 5mg / 5mg Open-Label and Safety Follow-Up PeriodTZP 10mg / 10mg Open-Label and Safety Follow-Up PeriodPlacebo/TZP 5mg Open-Label and Safety Follow-Up Period
AppendicitisInfections and infestations1/320/330/340/320/330/32
CholecystitisHepatobiliary disorders0/320/330/341/320/330/32
MastoiditisInfections and infestations0/321/330/340/320/330/32
Suicide attemptPsychiatric disorders0/320/331/340/321/330/32
DepressionPsychiatric disorders0/320/330/340/321/330/32
Borderline personality disorderPsychiatric disorders0/320/331/340/320/330/32
Suicidal ideationPsychiatric disorders0/320/331/340/320/330/32
Most frequent other events
Showing 10 of 20
Most frequent other events
Event5 mg Tirzepatide / Double-Blind PeriodTZP 10mg / Double-Blind PeriodPlacebo / Double-Blind PeriodTZP 5mg / 5mg Open-Label and Safety Follow-Up PeriodTZP 10mg / 10mg Open-Label and Safety Follow-Up PeriodPlacebo/TZP 5mg Open-Label and Safety Follow-Up Period
DiarrhoeaGastrointestinal disorders8/328/332/345/321/336/32
NauseaGastrointestinal disorders7/326/333/342/320/330/32
Abdominal painGastrointestinal disorders5/321/331/340/320/330/32
VomitingGastrointestinal disorders5/324/331/341/322/331/32
HyperglycaemiaMetabolism and nutrition disorders0/320/335/340/320/330/32
Abdominal pain upperGastrointestinal disorders2/324/333/340/320/330/32
DyspepsiaGastrointestinal disorders2/324/330/340/320/330/32
Decreased appetiteMetabolism and nutrition disorders0/324/330/340/320/330/32
DysmenorrhoeaReproductive system and breast disorders0/210/180/212/210/180/20
HeadacheNervous system disorders2/323/331/343/320/331/32

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)5 mg Tirzepatide10 mg TirzepatidePlaceboTotal
Mean15.00 ± 1.9314.60 ± 1.8314.60 ± 1.7914.70 ± 1.84
Sex: Female, Male
Sex: Female, Male(Participants)5 mg Tirzepatide10 mg TirzepatidePlaceboTotal
Female21182160
Male11151339
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)5 mg Tirzepatide10 mg TirzepatidePlaceboTotal
Hispanic or Latino24172465
Not Hispanic or Latino816933
Unknown or Not Reported0011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)5 mg Tirzepatide10 mg TirzepatidePlaceboTotal
American Indian or Alaska Native75820
Asian1236
Native Hawaiian or Other Pacific Islander1203
Black or African American54211
White17192157
More than one race1102
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)5 mg Tirzepatide10 mg TirzepatidePlaceboTotal
Australia1102
Brazil85316
India1236
Israel1438
Italy0213
Mexico1081331
United Kingdom0011
United States11111032
Hemoglobin A1c
Hemoglobin A1c(Percentage of HbA1c)5 mg Tirzepatide10 mg TirzepatidePlaceboTotal
Mean8.22 ± 1.177.89 ± 1.228.02 ± 1.308.04 ± 1.23
09

Study locations

51 sites
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Center Of Excellence in Diabetes and Endocrinology
    Sacramento, California 95821, United States
  • Rady Children's Hospital
    San Diego, California 92123, United States
  • Touro University California
    Vallejo, California 94592, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Nemours Children's Health - Delaware
    Wilmington, Delaware 19803, United States
  • Qualmedica Research, LLC
    Evansville, Indiana 47715, United States
  • Indiana University Health University Hospital
    Indianapolis, Indiana 46202, United States
  • AA Medical Research Center
    Flint, Michigan 48504, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Children's Hospital of Philadelphia (CHOP)
    Philadelphia, Pennsylvania 19104, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • The Children's Hospital at Westmead
    Westmead, New South Wales 2145, Australia
  • Centre for Children's Health Research
    Brisbane, Queensland 4101, Australia
  • Perth Children's Hospital
    Perth, Western Australia 6009, Australia
  • CEDOES
    Vitória, Espírito Santo 29055450, Brazil
  • Centro de Diabetes Curitiba
    Curitiba, Paraná 80810-040, Brazil
  • Instituto Méderi de Pesquisa e Saúde
    Passo Fundo, Rio Grande do Sul 99010-120, Brazil
  • Instituto da Crianca com Diabetes
    Porto Alegre, Rio Grande do Sul 91350-250, Brazil
  • Centro de Pesquisa Sao Lucas
    Campinas, São Paulo 13034-685, Brazil
  • Instituto de Pesquisa clinica de Campinas
    Campinas, São Paulo 13060-080, Brazil
  • Instituto de Pesquisa Clinica
    São Paulo, São Paulo 01223-001, Brazil
  • Instituto da Crianca do Hospital das Clinicas da FMUSP
    São Paulo, São Paulo 05403-000, Brazil
  • Ruschel Medicina e Pesquisa Clínica
    Rio de Janeiro, 22270-060, Brazil
  • CPQuali Pesquisa Clínica
    São Paulo, 01228-000, Brazil
  • CEPIC - Centro Paulista de Investigação Clínica
    São Paulo, 04266-010, Brazil
  • Centre Hospitalier Universitaire d'Angers
    Angers, Maine-et-Loire 49933, France
  • Assistance Publique - Hopitaux de Paris (AP-HP) - Hopital Robert Debre - Centre Hospitalo Universitaire (C -T
    Paris, 75019, France
  • Gujarat Endocrin Pvt Ltd
    Ahmedabad, Gujarat 380052, India
  • M S Ramaiah Medical College and Hospitals
    Bangalore, Karnataka 560054, India
  • Bhakti Vedanta Hospital and Research Institute
    Thane, Maharashtra 401107, India
  • All India Institute of Medical Sciences
    New Delhi, National Capital Territory of Delhi 110029, India
  • Kovai Diabetes Speciality Center and Hospital
    Coimbatore, Tamil Nadu 641009, India
  • Postgraduate Institute of Medical Education & Research
    Chandigarh, 160012, India
  • Yitzhak Shamir Medical Center
    Be’er Ya‘aqov, Central District 70300, Israel
  • Sheba Medical Center
    Ramat Gan, Central District 5262100, Israel
  • Shaare Zedek Medical Center
    Jerusalem, Jerusalem 9013102, Israel
  • Rambam Health Care Campus
    Haifa, Northern District 3109601, Israel
  • Soroka Medical Center
    Beersheba, Southern District 8410101, Israel
  • Azienda Ospedaliera Universitaria dell'Università "Luigi Vanvitelli" Piazza Luigi Miraglia, 2 Napoli Campa -T
    Naples, Campania 80138, Italy
  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento
    Verona, Veneto 37126, Italy
  • Ospedale Pediatrico Salesi
    Ancona, 60123, Italy
  • Unidad Médica para la Salud Integral
    San Nicolás de los Garza, Nuevo León 66465, Mexico
  • Clínica Cemain
    Tampico, Tamaulipas 89170, Mexico
  • Investigacion En Salud Y Metabolismo Sc
    Chihuahua City, 31217, Mexico
  • Consultorio Médico de Endocrinología y Pediatría
    Puebla City, 72190, Mexico
  • Arké SMO S.A de C.V
    Veracruz, 91910, Mexico
  • Leicester Royal Infirmary
    Leicester, England LE1 5WW, United Kingdom
  • Hull Royal Infirmary
    Hull, Kingston Upon Hull HU3 2JZ, United Kingdom
  • Leicester General Hospital
    Leicester, Leicestershire LE5 4PW, United Kingdom
10

References and documents

Publications

  • Hannon TS, Chao LC, Barrientos-Perez M, Pamidipati KC, Lando LF, Lee CJ, Patel H, Bergman BK. Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2025 Oct 4;406(10511):1484-1496. doi: 10.1016/S0140-6736(25)01774-X. Epub 2025 Sep 17. PubMed 40975112 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Jul 2024, 27 months.

Results were first posted in Sep 2025, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 27 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2022
First posted
Mar 2, 2022
StartActual
Apr 13, 2022
Primary completionActual
Jul 30, 2024
CompletionActual
Jan 28, 2025
Results first posted
Sep 26, 2025
Last update
Sep 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05260021
Responsible party
Sponsor
First posted
Mar 2, 2022
Start date
Apr 13, 2022
Primary completion
Jul 30, 2024
Completion
Jan 28, 2025
Results posted
Sep 26, 2025
Last update
Sep 26, 2025

Study contacts

1-877-CTLilly (1877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion